While Dyne Therapeutics Inc.’s DYNE-251 demonstrated high levels of dystrophin expression and functional improvement in boys with Duchenne muscular dystrophy who are amenable to exon 51 skipping, ...
Endpoints can include changes in levels of the therapeutic protein produced by the delivered gene (for example, Factor VIII or Factor IX for haemophilia A and B, respectively, or mini-dystrophin ...